poisar

Stocks · News reference

Shares of Tempus AI are trading higher amid possible sympathy with Merck and Moderna after the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint. The results may also boost sentiment around Tempus AI’s planned $1.5 billion acquisition of Personalis, whose genomic tumor-profiling technology supports the personalized vaccine used in the trial.

Aug 19, 2026, 6:06 PMBenzinga Newsdesk
Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TEM
Source
benzinga
Observed
Aug 19, 2026, 6:06 PM
Checked
Aug 19, 2026, 6:06 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aug 25, 2026, 4:46 PMBcc Research

    AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

    Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

    Read original at globenewswire-inc
    MRKRHHBYBMYCELGRNVS